Perioperative Regimen of Neoadjuvant Opdivo (nivolumab) and Chemotherapy Followed by Adjuvant Opdivo Shows Significant Improvement in Event-Free Survival for Patients with Resectable Non-Small Cell Lung Cancer in Phase 3 CheckMate -77T Trial

Neoadjuvant Opdivo with chemotherapy followed by surgery and adjuvant Opdivo reduced the risk of disease recurrence, progression or death by 42% in patients with resectable non-small cell lung...

Related Keywords

Japan ,South Korea ,United States ,Taiwan ,China ,Texas ,Tina Cascone ,Bristol Myers Squibb ,Abderrahim Oukessou ,Instagram ,Twitter ,European Society Of Medical Oncology ,Linkedin ,Facebook ,Youtube ,Exchange Commission ,European Union ,University Of Texas Md Anderson Cancer Center ,Company Opdivo ,Ono Pharmaceutical Co ,Blinded Independent Central Review ,Confidence Interval ,Presidential Symposium ,European Society ,Medical Oncology ,Neck Medical Oncology ,Bristol Myers ,Myers Squibb ,Better Future ,Fatal Immune Mediated Adverse ,Full Prescribing Information ,Allogeneic Hematopoietic Stem Cell ,Multiple Myeloma ,Thalidomide Analogue ,Prescribing Information ,Ono Pharmaceutical ,Private Securities Litigation Reform Act ,Annual Report ,Quarterly Reports ,Current Reports ,Markets ,